Northland Capital partners view on Motif Bio Plc LON:MTFB: In line with our expectations, Motif Bio announced that the last patient has finished treatment in its first pivotal Phase 3 trial (REVIVE-1) on iclaprim. The completion of patient treatment represents a significant milestone, as the trial is now firmly on target to deliver top line results in Q2-2017. A positive read out in this trial would likely trigger a significant rerating of the Group’s shares.
| Last patient has finished treatment phase in REVIVE-1 Phase 3 trial | ||||||||||||||||||||||||||||||||||||||||||||||||||
| n Motif Bio announced that the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).
n Data read-out is expected in the second quarter of 2017. n Data read-out for REVIVE-2 is anticipated in the second half of 2017. n Successful completion of the two REVIVE trials is expected to satisfy both US FDA and EMA requirements for regulatory submission for intravenous iclaprim in the treatment of ABSSSI. |
||||||||||||||||||||||||||||||||||||||||||||||||||
Source: Northland Capital Partners Limited.
|
